[go: up one dir, main page]

PE20010285A1 - Acidos 3-propilgamma-aminobutiricos mono- y disustituidos - Google Patents

Acidos 3-propilgamma-aminobutiricos mono- y disustituidos

Info

Publication number
PE20010285A1
PE20010285A1 PE2000000577A PE0005772000A PE20010285A1 PE 20010285 A1 PE20010285 A1 PE 20010285A1 PE 2000000577 A PE2000000577 A PE 2000000577A PE 0005772000 A PE0005772000 A PE 0005772000A PE 20010285 A1 PE20010285 A1 PE 20010285A1
Authority
PE
Peru
Prior art keywords
alkyl
propylgamma
disustituted
aminomethyl
mono
Prior art date
Application number
PE2000000577A
Other languages
English (en)
Inventor
Thomas Richard Belliotti
Justin Stephen Bryans
Ihoezo Victor Ekhato
Augustine Tobi Osuma
Po-Wai Yuen
Jacob Bradley Schwarz
Andrew John Thorpe
Lawrence David Wise
David Juergen Wustrow
Robert Michael Schelkun
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010285A1 publication Critical patent/PE20010285A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/20—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A ACIDOS 3-PROPILGAMMA AMINOBUTIRICOS MONO Y DISUSTITUIDOS DE FORMULA I, DONDE: R1 ES H, ALQUILO C1-C6, FENILO; R2 ES ALQUILO C1-C8; ALQUENILO C2-C8, CICLOALQUILO C3-C7, ALCOXI C1-C6, ALQUILCICLOALQUILO, ALQUILALCOXI, ENTRE OTROS; R1 ES ALQUILO C1-C6, FENILO CUANDO R2 ES METILO. SON COMPUESTOS PREFERIDOS ACIDO 3-AMINOMETIL-5-METILHEPTANOICO, ACIDO 3-AMINOMETIL-5-METIL-OCTANOICO, ACIDO (3R,4S)-3-AMINOMETIL-4,5-DIMETIL-HEXANOICO, ENTRE OTROS. EL COMPUESTO I PUEDE SER UTIL PARA EL TRATAMIENTO DE EPILEPSIA, ATAQUES DE DESMAYO, HIPOQUINESIA, TRASTORNOS CRANEANOS, TRASTORNOS NEURODEGENRATIVOS, DEPRESION, ANSIEDAD, PANICO, DOLOR, NEUROPATOLOGICOS, TRASTORNO DEL SUENO
PE2000000577A 1999-06-10 2000-06-09 Acidos 3-propilgamma-aminobutiricos mono- y disustituidos PE20010285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13848599P 1999-06-10 1999-06-10

Publications (1)

Publication Number Publication Date
PE20010285A1 true PE20010285A1 (es) 2001-03-22

Family

ID=22482232

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000577A PE20010285A1 (es) 1999-06-10 2000-06-09 Acidos 3-propilgamma-aminobutiricos mono- y disustituidos

Country Status (43)

Country Link
EP (1) EP1192125B9 (es)
JP (1) JP3904452B2 (es)
KR (1) KR100694735B1 (es)
CN (2) CN1196671C (es)
AP (1) AP1397A (es)
AR (1) AR033335A1 (es)
AT (1) ATE419231T1 (es)
AU (1) AU776723C (es)
BG (1) BG65561B1 (es)
BR (1) BR0011727A (es)
CA (2) CA2374755C (es)
CO (1) CO5200791A1 (es)
CR (1) CR6529A (es)
CU (1) CU23101A3 (es)
CY (1) CY1108827T1 (es)
CZ (2) CZ301608B6 (es)
DE (1) DE60041256D1 (es)
DK (1) DK1192125T3 (es)
DZ (1) DZ3253A1 (es)
EA (1) EA004398B1 (es)
EE (1) EE200100672A (es)
ES (1) ES2317839T3 (es)
GE (1) GEP20074142B (es)
HK (1) HK1046401B (es)
HR (1) HRP20020025A2 (es)
HU (1) HUP0201601A3 (es)
IL (2) IL146969A0 (es)
IS (1) IS6181A (es)
MA (1) MA26804A1 (es)
ME (1) MEP44808A (es)
MX (1) MXPA01012319A (es)
NO (2) NO327746B1 (es)
NZ (1) NZ515668A (es)
OA (1) OA11962A (es)
PE (1) PE20010285A1 (es)
PT (1) PT1192125E (es)
RS (2) RS20090257A (es)
SI (1) SI1192125T1 (es)
SK (2) SK287247B6 (es)
TR (1) TR200103587T2 (es)
UA (1) UA72519C2 (es)
WO (1) WO2000076958A2 (es)
ZA (1) ZA200109711B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
EP1469841A1 (en) 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands to treat tinnitus
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US20030225149A1 (en) * 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
RU2353358C2 (ru) 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
KR100845932B1 (ko) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ITMI20022658A1 (it) 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005025675A1 (en) 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
MXPA06003396A (es) 2003-09-25 2006-06-08 Warner Lambert Co Profarmacos de aminoacidos con afinidad por la proteina a 2d.
MXPA06003395A (es) * 2003-09-25 2006-06-08 Warner Lambert Co Aminoacidos con afinidad por la proteina a2d.
WO2006043171A2 (en) * 2004-10-23 2006-04-27 Warner-Lambert Company Llc Methods of using alpha2delta-1 selective compounds
EP1926710B1 (en) * 2005-09-15 2014-11-12 UCB Pharma S.A. 4-Substituted pyrrolidin-2-ones and their use
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
ES2367881T3 (es) 2006-12-22 2011-11-10 Recordati Ireland Limited Politerapia para trastornos de las vías urinarias inferiores con ligandos a2d y los aine.
WO2009136375A1 (en) * 2008-05-08 2009-11-12 Pfizer Inc Treatment of interstitial cystitis
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CN101914031B (zh) * 2010-07-30 2013-08-28 中国广州分析测试中心 普瑞巴林衍生物及其应用
US10100066B2 (en) * 2015-10-23 2018-10-16 Navitor Pharmaceuticals, Inc. Modulators of sestrin-GATOR2 interaction and uses thereof
AU2018258355B2 (en) 2017-04-26 2024-05-30 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
AU2019364542B2 (en) 2018-10-24 2025-08-28 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
WO2021087432A1 (en) 2019-11-01 2021-05-06 Navitor Pharmaceuticals, Inc. Methods of treatment using an mtorc1 modulator

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
ES2165857T3 (es) * 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
WO1998017627A1 (en) * 1996-10-23 1998-04-30 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
CN1303059C (zh) * 1997-10-27 2007-03-07 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物

Also Published As

Publication number Publication date
NO327746B1 (no) 2009-09-14
OA11962A (en) 2006-04-17
IL146969A (en) 2008-03-20
HUP0201601A2 (en) 2002-10-28
UA72519C2 (en) 2005-03-15
RS20090257A (sr) 2010-03-02
PT1192125E (pt) 2009-03-05
WO2000076958A3 (en) 2001-04-12
EP1192125B1 (en) 2008-12-31
BG106292A (bg) 2002-05-31
EE200100672A (et) 2003-02-17
CN1310872C (zh) 2007-04-18
HK1046401B (zh) 2005-12-02
CN1355784A (zh) 2002-06-26
TR200103587T2 (tr) 2002-04-22
HK1046401A1 (en) 2003-01-10
CN1196671C (zh) 2005-04-13
CY1108827T1 (el) 2014-04-09
MXPA01012319A (es) 2002-07-22
EA200101134A1 (ru) 2002-06-27
CA2374755C (en) 2010-03-30
JP3904452B2 (ja) 2007-04-11
SK17642001A3 (sk) 2002-10-08
CA2374755A1 (en) 2000-12-21
EP1192125B9 (en) 2009-09-16
MEP44808A (en) 2011-02-10
IS6181A (is) 2001-11-28
HK1076626A1 (en) 2006-01-20
GEP20074142B (en) 2007-07-10
AU776723B2 (en) 2004-09-16
BR0011727A (pt) 2002-03-05
SI1192125T1 (sl) 2009-04-30
MA26804A1 (fr) 2004-12-20
NO20015949L (no) 2001-12-05
HUP0201601A3 (en) 2002-11-28
ES2317839T3 (es) 2009-05-01
CU23101A3 (es) 2005-12-20
EP1192125A2 (en) 2002-04-03
ATE419231T1 (de) 2009-01-15
PL352431A1 (en) 2003-08-25
SK287247B6 (sk) 2010-04-07
JP2003502308A (ja) 2003-01-21
AR033335A1 (es) 2003-12-17
AU5311900A (en) 2001-01-02
CZ300834B6 (cs) 2009-08-19
DE60041256D1 (de) 2009-02-12
HRP20020025A2 (en) 2003-12-31
CN1660779A (zh) 2005-08-31
DK1192125T3 (da) 2009-02-16
KR100694735B1 (ko) 2007-03-14
YU87001A (sh) 2004-07-15
IL146969A0 (en) 2002-08-14
RS50352B (sr) 2009-11-10
SK287399B6 (sk) 2010-08-09
AP1397A (en) 2005-04-19
DZ3253A1 (fr) 2000-12-21
CZ20014285A3 (cs) 2002-07-17
CZ301608B6 (cs) 2010-04-28
NO20015949D0 (no) 2001-12-05
ZA200109711B (en) 2003-03-20
AP2002002388A0 (en) 2002-03-31
CO5200791A1 (es) 2002-09-27
BG65561B1 (bg) 2008-12-30
EA004398B1 (ru) 2004-04-29
NZ515668A (en) 2004-02-27
CR6529A (es) 2003-11-25
NO20091094L (no) 2001-12-05
KR20020009631A (ko) 2002-02-01
WO2000076958A2 (en) 2000-12-21
AU776723C (en) 2005-06-02
CA2689997A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
PE20010285A1 (es) Acidos 3-propilgamma-aminobutiricos mono- y disustituidos
PE20021031A1 (es) Aminoacidos biciclicos o triciclicos condensados
TR200001800T2 (tr) -4(3)-İkameli -4(3)- aminometil-(tio) piran veya- piperidin türevleri (=Gabapentin analogları), hazırlanmaları ve nörolojik hastalıkların tedavisinde kullanımları
DE69921340D1 (de) Verzweigte alkylpyrrolidin-3-carbonsäuren
PE122799A1 (es) Aminoacidos ciclicos y sus derivados utiles como agentes farmaceuticos
RU96124481A (ru) Аналоги gaba и l-глутаминовой кислоты, способ их получения, способ лечения и фармацевтическая композиция
KR900012906A (ko) 진통제로서 유용한 n-페닐-n-(4-피페리디닐)아미드
UA70958C2 (uk) Спосіб лікування захворювання, пов'язаного з порушенням метаболізму естрогену (варіанти)
JP2003502308A5 (es)
PE20040555A1 (es) Profarmacos de aminoacidos excitadores
CA2407659A1 (en) Growth hormone secretagogues
PE20040175A1 (es) Metodo para tratar enfermedades o condiciones desmielinizantes
PE20020191A1 (es) Pirrolidinas 1,3-disustituidas y 1,3,3-trisustituidas como ligandos del receptor de histamina y sus aplicaciones terapeuticas
KR900004323B1 (ko) 1,3-옥사졸리딘-2-온 유도체의 제조방법
RU2003102436A (ru) Нейропротекторные 7-бета-гидроксистероиды
WO2003105779A3 (en) Guanidine compounds as anesthetics and for treatment of nervous system disorders
Howse Metabolic responses to status epilepticus in the rat, cat, and mouse
CO5080731A1 (es) Compuestos de tetrahidroisoquinolinil-carboxamida y composiciones que los contienen
BR0010961A (pt) Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono
JP2001525390A (ja) 抗痙攣薬および中枢神経系活性ビス（フルオロフェニル）アルキルアミド類
KR880009944A (ko) 피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물
US20240208935A1 (en) Compositions and methods for treating neurodegenerative diseases
US6969732B2 (en) Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
US4500531A (en) Therapeutical use of (1-cinnamoyl or 1-phenethylcarbonyl) piperazine derivatives
RU2008101776A (ru) Соединения для ингибирования обратного захвата 5-гидрокситриптамина и норэпинефрина или для лечения депрессивных состояний, способы их получения и применения

Legal Events

Date Code Title Description
FC Refusal